Insights into the mechanism of organ-specific cancer metastasis

Cancer Discovery

Volumn 4, Issue 11, 2014, Pages 1262-1264

  Rubin, Mark A ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; NERVE CELL ADHESION MOLECULE; SCATTER FACTOR RECEPTOR; SERINE PROTEINASE; TRANSMEMBRANE SERINE PROTEASE TYPE II; UNCLASSIFIED DRUG; TMPRSS2 PROTEIN, HUMAN;

ARTICLE; COMBINATORIAL LIBRARY; DISEASE COURSE; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; METASTASIS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; COLON; GENETICS; LUNG; MALE; METABOLISM; MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

ANIMALS; COLON; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES;

EID: 84908424001     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1075     Document Type: Article

References (12)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366: 2517-9.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
5. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
6. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fi broblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110: 20212-7.
7. Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True L D, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 2014;4: 1310-25.
8. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, et al. Prostate-localized and androgen-regulated expression of the membranebound serine protease TMPRSS2. Cancer Res 1999; 59: 4180-4.
9. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6.
10. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 2008; 215: 118-25.
11. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-68.
12. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 200; 310: 644-8.